Marinus Pharma scores $12M option from HHS to produce active ingredient for anti-seizure drug

SourceFierce Pharma
Date Published09/22/2022
Author NameJoseph Keenan
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Marinus Pharma
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2022
Capital investment ($):12.3
City reshored to:Radnor
State(s) reshored to:PA
If relevant, work nearshored to:-
Product(s) reshoredganaxolone
What domestic positive factors made reshoring more attractive?Government Incentives, HHS BARDA
Find Reshoring Articles